News
Top news
2021
- 1 March 2021
- 16 February 2021
2020
- 1 December 2020
- 14 October 2020
- 10 October 2020
- 22 September 2020
- 15 September 2020
2019
- 3 April 2019
2018
- 30 October 2018
- 16 October 2018
Statements and background on the CRISPR patent landscape
- 10 March 2021
ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement
- 3 March 2021
ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical
- 1 March 2021
ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development
Questions and answers about CRISPR patents
CVC’s issued patents are to the composition and use of the core type 2 CRISPR/Cas9 complex to modify DNA in ANY ENVIRONMENT without limitation to uses in eukaryotic cells. CVC further has issued patents on single guide RNA (sgRNA) which greatly enhances the efficiency of CRISPR gene editing in many applications.
In the United States, Broad’s issued patents (currently subject to a PTAB initiated interference) are for certain methods of genome editing and uses only in eukaryotic cells.
In December, 2012, Broad requested “accelerated examination” of its application. This meant the USPTO considered the application more quickly. CVC did not request accelerated examination when it applied for a patent in May, 2012.
CRISPR research is a large field that involves contributions from many talented scientists around the world. The USPTO had issued more than 570 patents as of September 2020, with claims to CRISPR and/or Cas9 to approximately 900 inventors from more than 200 applicant organizations. The European Patent Office (EPO) had issued more than 190 such patents to more than 460 inventors from about 110 applicant institutions. In addition, there have been more than 9,200 applications filed (and published but not yet granted) around the world.
Current CVC patent list can be viewed here.
Over the next several years, there will be many more patents issued in the CRISPR field, to many inventors from many institutions, in recognition of each individual’s contribution to advancing CRISPR technology.
Latest news

ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement
DUBLIN, Ireland & Tokushima, Japan, 10 March 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro Tech, a biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, today announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.